Recent Advances on the Chemical Composition, Pharmacological Properties, and Product Development of Morus alba
Phytochemical Analysis · 2025-07 · 36 (5) · 1301-1332
DOI: 10.1002/pca.3544 ↗At a glance
Übersichtsarbeit in Phytochemical Analysis, published online on 2025-05-30. Written by Zixuan Yan and 5 co-authors. Institution: College of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China. Major MEDLINE topics: Morus, Phytochemicals, Plant Extracts. Cited 13 times so far (Crossref); 182 references. Funded by: Anhui Huatuo Academy of Traditional Chinese Medicine, First Batch of Science and Technology Special Mission Projects in Anhui Province.
Abstract (original language)
Introduction
Morus alba , a member of the Moraceae family, has a long history of medicinal use in China. Its branches, fruits, leaves, and root bark are rich in various bioactive compounds, including flavonoids, alkaloids, and other phytochemicals. These plant parts exhibit a broad spectrum of pharmacological activities, such as antidiabetic, antitumor, antibacterial, and antioxidant effects. Owing to these properties, various parts of M. alba have been developed into functional foods and health products, attracting considerable public and scientific interest.
Objectives
This review aims to summarize current knowledge on the phytochemistry, pharmacological activities, and product development related to different parts of M. alba , with particular emphasis on their respective roles in the development of functional products.
Methods
Relevant literature was retrieved from major scientific databases, including PubMed, Web of Science, ScienceDirect, and Google Scholar. Information related to the phytochemistry, pharmacological effects, and product development of various parts of M. alba was systematically collected and analyzed.
Results
This review summarizes the chemical composition of different parts of M. alba and their corresponding pharmacological properties. It also highlights recent advancements in the development of functional products derived from M. alba .
Conclusions
M.orus alba contains a wide array of bioactive compounds with promising pharmacological potential. Its various parts have demonstrated potential in the prevention and management of chronic diseases and have been increasingly utilized in the development of functional health products. Further interdisciplinary studies are warranted to facilitate its translational application in modern healthcare.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Tianjin Key Laboratory of Intelligent and Green Pharmaceuticals for Traditional Chinese Medicine, Tianjin, China.
- School of Chinese Medicine, Bozhou University, Bozhou, China.
- Anhui Huatuo Academy of Traditional Chinese Medicine, Bozhou Vocational and Technical College, Bozhou, China.
ORCID profiles: Wenlong Li
Funding
- Anhui Huatuo Academy of Traditional Chinese Medicine
- First Batch of Science and Technology Special Mission Projects in Anhui Province
Cite
APA
Yan, Z., Alimujiang, S., Zhang, Y., Zhao, J., Hu, Y., & Li, W. (2025). Recent Advances on the Chemical Composition, Pharmacological Properties, and Product Development of Morus alba. Phytochemical Analysis, 36(5), 1301-1332. https://doi.org/10.1002/pca.3544
Vancouver
Yan Z, Alimujiang S, Zhang Y, Zhao J, Hu Y, Li W. Recent Advances on the Chemical Composition, Pharmacological Properties, and Product Development of Morus alba. Phytochemical Analysis. 2025;36(5):1301-1332. doi:10.1002/pca.3544
BibTeX
@article{Yan2025,
author = {Yan, Zixuan and Alimujiang, Shamukaer and Zhang, Yao and Zhao, Jianqiang and Hu, Yunfei and Li, Wenlong},
title = {Recent Advances on the Chemical Composition, Pharmacological Properties, and Product Development of Morus alba},
journal = {Phytochemical Analysis},
year = {2025},
volume = {36},
number = {5},
pages = {1301--1332},
doi = {10.1002/pca.3544}
}
EUVIMED